Home drugs Kadcyla (Ado-Trastuzumab Emtansine)

Kadcyla (Ado-Trastuzumab Emtansine)

This page contains brief information about ado-trastuzumab emtansine and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)      Kadcyla
FDA Approved            Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Ado-trastuzumab emtansine is approved to treat:

  • Breast cancer that is HER2 positive and has metastasized (spread to other parts of the body). It is used in patients who have already been treated with trastuzumab and a taxane. It is also used in these patients if the cancer recurs(comes back) after adjuvant therapy.

Ado-trastuzumab emtansine is also being studied in the treatment of other types of cancer.

More About Ado-Trastuzumab Emtansine

Definition from the TCH Drug Dictionary – Detailed scientific definition and other names for this drug.

MedlinePlus Information on Ado-Trastuzumab Emtansine – A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.